BIOPHYTIS (ALBPS.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALBPS - FR001400OLP5 - Common Stock
ALBPS.PA Key Statistics, Chart & Performance
The current stock price of ALBPS.PA is 0.08 EUR. In the past month the price decreased by -34.75%. In the past year, price decreased by -74.19%.
ALBPS.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 72.89 | 48.33B | ||
| 1AE.DE | ARGENX SE | 72.72 | 48.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.56B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.44B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.76B | ||
| 5CV.DE | CUREVAC NV | 5.09 | 996.15M | ||
| NANO.PA | NANOBIOTIX | N/A | 869.81M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 547.70M | ||
| ALCLS.PA | CELLECTIS | N/A | 453.47M | ||
| FYB.DE | FORMYCON AG | N/A | 423.20M |
Related stock screener links
About ALBPS.PA
Company Profile
Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 18 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
Company Info
BIOPHYTIS
14 avenue de l'Opera
Paris ILE-DE-FRANCE FR
Employees: 22
Phone: 33141836600
BIOPHYTIS / ALBPS.PA FAQ
What does ALBPS do?
Biophytis SA operates as a clinical-stage biotechnology company. The company is headquartered in Paris, Ile-De-France and currently employs 18 full-time employees. The company went IPO on 2015-07-13. The firm is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
What is the stock price of BIOPHYTIS today?
The current stock price of ALBPS.PA is 0.08 EUR.
What is the dividend status of BIOPHYTIS?
ALBPS.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALBPS stock?
ALBPS.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What do analysts say about BIOPHYTIS (ALBPS.PA) stock?
9 analysts have analysed ALBPS.PA and the average price target is 0.79 EUR. This implies a price increase of 881.75% is expected in the next year compared to the current price of 0.08.
ALBPS.PA Technical Analysis
ALBPS.PA Financial Highlights
Over the last trailing twelve months ALBPS.PA reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 87.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -121.24% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALBPS.PA Forecast & Estimates
9 analysts have analysed ALBPS.PA and the average price target is 0.79 EUR. This implies a price increase of 881.75% is expected in the next year compared to the current price of 0.08.
For the next year, analysts expect an EPS growth of 48.09% and a revenue growth -78.57% for ALBPS.PA